mRNA

Moderna Stock Soars on COVID Vaccine Results
Risk & Compliance

Moderna Stock Soars on COVID Vaccine Results

Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
By Matthew Heller | May 18, 2020
Read More
Biotech’s Moderna Poised for Market Debut
IPOs

Biotech’s Moderna Poised for Market Debut

The startup's IPO would raise capital for "a new category of transformative medicines based on messenger RNA."
By Matthew Heller | December 6, 2018
Read More